Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody. | Boehringer Ingelheim has penned a 1.

The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...

Single-center study finds durable, steroid-free remission, especially in ulcerative coliti ...

But prior pelvic surgery may impair female fertility, according to ongoing WiSDoM trial ...

Real-world analyses suggest link to reduced steroid use, fewer hospital stays, lower morta ...

Although inflammatory bowel disease (IBD) starts in the gut, it doesn’t always stay there. According to a 2015 study in the journal Inflammatory Bowel Disease, up to 47% of people with IBD will ...

It can be overwhelming to receive a diagnosis of inflammatory bowel disease (IBD), a condition which refers to the chronic diseases that can cause inflammation in your gastrointestinal (GI) tract.

Meta-analysis links caffeine consumption to higher inflammatory bowel disease risk in smokers, those with more education, and ...

Immune signaling in IBD triggers tumor-promoting neutrophils which is linked to an increased risk of colorectal cancer.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients infected with SARS-CoV-2 during the first wave ...